Clik here to view.
Report: Next-gen Amazon Alexa could detect illness, provide medicine suggestions
Future generations of Amazon‘s (NSDQ:AMZN) Alexa virtual assistant may be able to determine when its users are ill and provide medication recommendations, according to a new report from The Telegraph....
View ArticleClik here to view.
Tandem wins approval for insulin pump in Canada
Tandem Diabetes Care (NSDQ:TNDM) won a medical device license from Health Canada last week for its t:slim X2 insulin pump. The device integrates directly with Dexcom‘s (NSDQ:DXCM) G5 continuous glucose...
View ArticleClik here to view.
Vascular Therapies raises $12m for drug-eluting vascular access implant
Vascular Therapies has raised $12.4 million from 29 investors as part of a $21.1 million round, according to a document filed last week with the SEC. The Cresskill, N.J.-based company is developing a...
View ArticleClik here to view.
Valeritas shares fall despite Street-beating Q3 prelims
Shares in Valeritas (NSDQ:VLRX) fell today after the medical technology company announced its preliminary financial results for the third quarter of 2018. The Bridgewater, N.J.-based company said it...
View ArticleClik here to view.
Kala seeks FDA nod for dry eye disease drug
Kala Pharmaceuticals (NSDQ:KALA) said today that it submitted a new drug application to the FDA for its KPI-121 0.25% topical product designed for patients with dry eye disease. The Waltham,...
View ArticleClik here to view.
Medtronic launches workflow system to help wean patients off oral opioids
Medtronic (NYSE:MDT) said today that it launched its Control Workflow system in the U.S. for use with its SynchroMed II intrathecal drug-delivery system. The medtech titan is hoping that, combined with...
View ArticleClik here to view.
FDA approves five-year hormonal contraceptive
Allergan (NYSE:AGN) and the nonprofit women’s health pharma company Medicines360 said today that the FDA approved an application to extend the duration of use for Liletta for the prevention of...
View ArticleClik here to view.
Valeritas aims for $50m in stock offering
Valeritas (NSDQ:VLRX) said this week that it plans to offer 37,593,984 shares of its common stock, hoping to raise $50 million in gross proceeds. The medical technology company also announced its...
View ArticleClik here to view.
Phillips-Medisize inks deal to develop connected health platform for drugs
Phillips-Medisize said this week that it teamed up with healthcare software tech company InterSystems to develop a data-sharing and analytics platform designed for connected drug-delivery devices and...
View ArticleClik here to view.
Nanobiotix reels in $18.5m tranche from European Investment Bank
Nanobiotix (PAR:NANO.PA) received €16 million ($18.5 million) in the first tranche of a previously-announced non-dilutive loan from the European Investment Bank. The five-year funding deal is designed...
View ArticleClik here to view.
Anthem, Novo Nordisk team up for real-world diabetes drug study
Anthem’s outcomes research unit, HealthCore, and Novo Nordisk (NYSE:NVO) have joined forces to study Novo Nordisk’s semaglutide GLP-1 receptor agonist in people with Type 2 diabetes. The real-world...
View ArticleClik here to view.
Valeritas launches wearable insulin delivery device in Italy
Valeritas (NSDQ:VLRX) said today that its wearable insulin delivery device has launched in Italy. The Bridgewater, N.J.-based company inked an exclusive distribution deal with Movi SpA to bring its...
View ArticleClik here to view.
AcelRx shares fall as Sen. Markey calls on FDA to reject opioid painkiller
Shares in AcelRx (NSDQ:ACRX) fell last week after U.S. Sen. Ed Markey (D-Mass) called on the FDA to reject the drugmaker’s opioid painkiller, Dsuvia. The senator noted that the product, which is...
View ArticleClik here to view.
Novocure touts Phase II pancreatic cancer pilot study
Novocure (NSDQ:NVCR) today touted the results of a Phase II pilot trial designed to test the feasibility, safety and efficacy of its Tumor Treating Fields therapy in patients with unresectable,...
View ArticleClik here to view.
Flexion reports data from Phase II bilateral osteoarthritis trial
Flexion Therapeutics (NSDQ:FLXN) touted data today from a Phase II trial assessing the bilateral dosing of its extended-release triamcinolone acetonide injection in people with bilateral...
View ArticleClik here to view.
Beta Bionics raises $58m for iLet bionic pancreas
Beta Bionics has raised $57.5 million from 24 investors to help fund the development of its iLet bionic pancreas, according to a document filed with the SEC this week. The Mass.-based company is...
View ArticleClik here to view.
Novo Nordisk partners with Flex for digital diabetes management tools
Flex (NSDQ:FLEX) today announced a partnership with Novo Nordisk (NYSE:NVO) to develop digital diabetes management tools using Flex’s BrightInsight IoT platform. Novo Nordisk plans to use Flex’s...
View ArticleClik here to view.
FDA to review Xeris’ glucagon rescue pen auto-injector
Xeris Pharmaceuticals (NSDQ:XERS) said today that the FDA accepted its new drug application for a ready-to-use liquid glucagon rescue pen device. The company’s product is designed to treat severe...
View ArticleClik here to view.
ICU Medical warns about leaks in Thermoset drug-delivery systems
ICU Medical (NSDQ:ICUI) issued a warning this month that it received reports of leakage with some lots of its Thermoset drug-delivery systems in Europe, the Middle East and Africa. The company noted...
View ArticleClik here to view.
Boston Scientific CEO talks pricing pressure for drug-eluting stents
On an earnings call with analysts this week, Boston Scientific (NYSE:BSX) CEO Mike Mahoney touted the momentum of his company’s drug-eluting stent portfolio but noted that the technologies continue to...
View Article